ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $48,573,000 | +202.0% | 282,238 | +120.2% | 0.01% | +400.0% |
| Q2 2021 | $16,082,000 | +26.3% | 128,150 | +36.5% | 0.00% | 0.0% |
| Q1 2021 | $12,732,000 | -11.7% | 93,886 | -16.7% | 0.00% | -50.0% |
| Q4 2020 | $14,425,000 | +13.4% | 112,736 | -0.3% | 0.00% | 0.0% |
| Q3 2020 | $12,719,000 | +18.3% | 113,024 | +0.2% | 0.00% | 0.0% |
| Q2 2020 | $10,750,000 | +37.4% | 112,840 | +29.6% | 0.00% | +100.0% |
| Q1 2020 | $7,823,000 | -12.6% | 87,042 | -48.4% | 0.00% | 0.0% |
| Q4 2019 | $8,952,000 | +175.5% | 168,838 | +105.3% | 0.00% | – |
| Q3 2019 | $3,249,000 | -24.3% | 82,227 | -21.3% | 0.00% | -100.0% |
| Q2 2019 | $4,291,000 | -26.9% | 104,480 | -17.1% | 0.00% | 0.0% |
| Q1 2019 | $5,868,000 | +168.3% | 126,020 | +151.0% | 0.00% | – |
| Q4 2018 | $2,187,000 | -12.8% | 50,209 | +14.5% | 0.00% | – |
| Q3 2018 | $2,509,000 | -37.9% | 43,843 | -47.3% | 0.00% | -100.0% |
| Q2 2018 | $4,039,000 | +80.6% | 83,241 | +45.5% | 0.00% | – |
| Q1 2018 | $2,237,000 | +3.2% | 57,195 | +12.0% | 0.00% | – |
| Q4 2017 | $2,168,000 | -57.7% | 51,088 | -62.8% | 0.00% | -100.0% |
| Q3 2017 | $5,131,000 | +57.3% | 137,468 | +28.0% | 0.00% | – |
| Q2 2017 | $3,262,000 | -1.8% | 107,406 | -14.4% | 0.00% | – |
| Q1 2017 | $3,322,000 | +47.1% | 125,508 | +41.8% | 0.00% | – |
| Q4 2016 | $2,258,000 | +41.3% | 88,480 | +100.4% | 0.00% | – |
| Q3 2016 | $1,598,000 | +1.5% | 44,151 | -4.7% | 0.00% | – |
| Q2 2016 | $1,575,000 | +34.3% | 46,325 | +4.2% | 0.00% | – |
| Q1 2016 | $1,173,000 | -52.2% | 44,447 | -11.7% | 0.00% | -100.0% |
| Q4 2015 | $2,454,000 | +6911.4% | 50,329 | +3474.5% | 0.00% | – |
| Q3 2015 | $35,000 | -64.6% | 1,408 | -55.0% | 0.00% | – |
| Q2 2015 | $99,000 | -90.1% | 3,131 | -88.0% | 0.00% | – |
| Q1 2015 | $996,000 | +2453.8% | 26,146 | +2514.6% | 0.00% | – |
| Q4 2014 | $39,000 | +8.3% | 1,000 | -14.8% | 0.00% | – |
| Q3 2014 | $36,000 | -16.3% | 1,174 | -7.8% | 0.00% | – |
| Q2 2014 | $43,000 | – | 1,273 | +8992.9% | 0.00% | – |
| Q1 2014 | $0 | – | 14 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |